See more : Matching Service Japan Co., Ltd. (6539.T) Income Statement Analysis – Financial Results
Complete financial analysis of CARGO Therapeutics, Inc. Common Stock (CRGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CARGO Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Dassault Aviation Société anonyme (DUAVF) Income Statement Analysis – Financial Results
- Environmental Waste International Inc. (YEWTF) Income Statement Analysis – Financial Results
- Tempus Holdings Limited (6880.HK) Income Statement Analysis – Financial Results
- Guangshen Railway Company Limited (0525.HK) Income Statement Analysis – Financial Results
- Bangkok Dusit Medical Services Public Company Limited (BDMS-R.BK) Income Statement Analysis – Financial Results
CARGO Therapeutics, Inc. Common Stock (CRGX)
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.69M | 1.44M | 147.00K |
| Gross Profit | -3.69M | -1.44M | -147.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 75.79M | 29.37M | 4.46M |
| General & Administrative | 20.92M | 5.40M | 1.52M |
| Selling & Marketing | -3.69M | 0.00 | 0.00 |
| SG&A | 17.23M | 5.40M | 1.52M |
| Other Expenses | 0.00 | -22.00K | 127.00K |
| Operating Expenses | 93.02M | 34.77M | 5.98M |
| Cost & Expenses | 96.71M | 34.77M | 5.98M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.60M | 4.94M | 0.00 |
| Depreciation & Amortization | 3.69M | 1.44M | 147.00K |
| EBITDA | -93.02M | -33.35M | -5.70M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -96.71M | -34.77M | -5.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.44M | -6.18M | 127.00K |
| Income Before Tax | -98.15M | -40.95M | -5.85M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.92M | 127.00K |
| Net Income | -98.15M | -40.95M | -5.85M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -2.38 | -2.13 | -0.30 |
| EPS Diluted | -2.38 | -2.13 | -0.30 |
| Weighted Avg Shares Out | 41.21M | 19.23M | 19.47M |
| Weighted Avg Shares Out (Dil) | 41.21M | 19.23M | 19.47M |
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
IPO watch 2024: Which new stocks will hit the market?
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
3 New Stock Listings That Can Deliver Multibagger Returns
U.S. IPO Weekly Recap: Reinsurance And CAR T Therapies Lead A 3 IPO Week
Cargo Therapeutics IPO prices at $15 a share, low end of proposed range
Source: https://incomestatements.info
Category: Stock Reports